AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: RYBELSUS (Novo Nordisk) (rybelsus.com)
This is a rare example of a low-bullshit website where the marketing signal is almost entirely replaced by clinical substance. The site’s only significant failures are technical and structural rather than rhetorical. It functions more as a digital data sheet than a typical marketing landing page.
Implement Medication and Organization schema to the homepage to bridge the technical authority gap. Replace generic patient imagery with links to specific ClinicalTrials.gov study IDs to provide a verified proof path. Resolve the duplicate H2 heading tags and broken heading hierarchy on sub-pages to improve technical credibility. Add Person schema for any featured patient testimonials to move beyond trust theatre proxies.
The information density is exceptionally high for a commercial site, with a low ratio of power-word fluff to substantive data. Headings like RYBELSUS lowered blood sugar better than a leading branded pill are immediately followed by specific metrics such as -1.3% on 14 mg of RYBELSUS compared to -0.8% on 100 mg of JANUVIA. Body text avoids vague adjectives in favor of technical protocols, citing a 6-month medical study in 1864 adults. The site prioritizes clinical results over revolutionary marketing slogans, creating a high substance-to-signal ratio.
A validator checks tags. An AI system checks whether your identity is stable across all crawl paths. Start your free canonical interpretation to see how your URLs are actually resolved by LLMs.
There is virtually zero semantic drift between the homepage promises and sub-page delivery. The homepage H1 Get your A1C Down is quantitatively supported on the Results sub-page, which details that the majority of people taking the drug reached an A1C of less than 7%. Messaging remains consistent regarding weight loss, clearly stating it is not for weight loss while providing the 8-pound average loss data to prevent over-claiming. The transition from the hero section to deeper comparison pages maintains a unified clinical tone without shifting target audiences.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site avoids common trust theatre traps like unverified customer review carousels, as evidenced by a review_count of 0 across all pages. However, it relies heavily on internal summaries of studies rather than providing direct outbound proof_links_count to peer-reviewed journals or ClinicalTrials.gov identifiers in the crawled text. While the data provided is granular (e.g., 3183 adults in a CV safety study), the lack of external verification paths in the metadata increases the score slightly. The presence of a trust_theatre_flag is false, which is consistent with its clinical focus.
The proof density is high, with more than 8 distinct instances of specific clinical evidence across the pages including exact participant numbers (1864, 703, 3183) and weight loss metrics (8.4 lbs vs 8.1 lbs). Vague assertions are kept to a minimum, with most sentences serving as a delivery vehicle for a data point. The site effectively uses comparative data against named competitors like JANUVIA and JARDIANCE to establish substance.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses standard pharmaceutical template structures but populates them with highly specific drug-related data. Clichés like once-daily and proven are used, but they are tethered to specific pharmaceutical mechanisms and dosages rather than generic business benefits. The value proposition is entirely unique to the semaglutide molecule and cannot be copy-pasted onto a generic competitor without losing all meaning. The only commodity markers are the boilerplate Important Safety Information blocks required by law, which are exempt from typical fluff penalties.
Authority is the weakest pillar due to a total absence of structured data, with schema_json returning null on every page. There is a disconnect between the brand’s global pharma status and its technical implementation, which lacks Organization or Medication schema. Furthermore, the use of a testimonial figure Troy standing with his dog lacks any Person schema or digital authority footprint to verify his status as a real patient. The technical implementation also suffers from minor issues like duplicate H2 headings (RYBELSUS—All of This in 1 Pill) on the Results page.
The site’s performance claims are strictly bound to clinical study results rather than marketing hyperbole. For every claim of efficacy, such as lowered blood sugar better, the site provides the average starting A1C (8.3%) and the specific delta for each dose. This level of transparency is rare and demonstrates high substance. There are no bold claims of life-changing transformations that aren’t immediately qualified by individual results may vary.
Medical Devices, Pharma & Biotech BS: RYBELSUS (Novo Nordisk) (rybelsus.com)
The website perfectly aligns with the Pharma & Biotech category, focusing on a specific therapeutic area (Type 2 Diabetes) and utilizing appropriate medical jargon. The content is heavily regulated, emphasizing Important Safety Information and clinical trial outcomes consistent with FDA-governed pharmaceutical marketing.
If your entity graph is unstable, every other part of the framework inherits that instability. Study the Structured Data Framework Guide and see why schema is not markup — it is the machine readable definition of your domain.
“The score of 24 is primarily driven by the Identity and Authority pillar (10/15) due to the complete lack of schema_json and technical heading errors. Information Density and Semantic Coherence scored near-perfectly because the site backs every marketing claim with specific clinical metrics. The low BS score reflects a site that values data over persuasion, which is appropriate for its highly regulated industry.”